Oncology tests surged 176% while prenatal revenue climbed 55%, driving 64% overall growth.

Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise.

BillionToOne (BLLN) is back in focus after its August 5 update, when the company reported second quarter 2026 results and reaffirmed its full-year revenue outlook in the mid US$400 million range. See our latest analysis for BillionToOne. The recent earnings beat and reiterated 2026 revenue guidance have been met with strong buying interest, with BillionToOne’s share price return of 61.4% over 90 days and 68.0% year to date signaling firm positive momentum. If BillionToOne’s move has caught...

Moby summary of BillionToOne, Inc.'s Q2 2026 earnings call

BillionToOne Inc (BLLN) posts strong Q2 with record revenue, expanding margins, and strategic momentum in oncology and prenatal testing.

While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Billiontoone (NASDAQ:BLLN) reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular diagnostics company also posted positive operating income and free cash flow while reit

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.